CN116323613A - Wee1抑制剂的盐和形式 - Google Patents
Wee1抑制剂的盐和形式 Download PDFInfo
- Publication number
- CN116323613A CN116323613A CN202180055999.8A CN202180055999A CN116323613A CN 116323613 A CN116323613 A CN 116323613A CN 202180055999 A CN202180055999 A CN 202180055999A CN 116323613 A CN116323613 A CN 116323613A
- Authority
- CN
- China
- Prior art keywords
- degrees
- cancer
- compound
- range
- free base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063049996P | 2020-07-09 | 2020-07-09 | |
| US63/049,996 | 2020-07-09 | ||
| PCT/US2021/070851 WO2022011391A1 (en) | 2020-07-09 | 2021-07-08 | Salts and forms of a wee1 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116323613A true CN116323613A (zh) | 2023-06-23 |
Family
ID=79552745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180055999.8A Pending CN116323613A (zh) | 2020-07-09 | 2021-07-08 | Wee1抑制剂的盐和形式 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12606567B2 (https=) |
| EP (1) | EP4178960A4 (https=) |
| JP (2) | JP2023533040A (https=) |
| KR (1) | KR20230038523A (https=) |
| CN (1) | CN116323613A (https=) |
| AU (1) | AU2021305347A1 (https=) |
| BR (1) | BR112023000350A2 (https=) |
| CA (1) | CA3188737A1 (https=) |
| MX (1) | MX2023000333A (https=) |
| TW (1) | TWI896701B (https=) |
| WO (1) | WO2022011391A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020384291A1 (en) | 2019-11-15 | 2022-05-26 | Recurium Ip Holdings, Llc | Chiral synthesis of a tertiary alcohol |
| CN116462687B (zh) * | 2022-01-18 | 2025-01-07 | 江苏天士力帝益药业有限公司 | Wee1抑制剂及其制备和用途 |
| EP4469086A4 (en) * | 2022-01-25 | 2026-01-21 | Verastem Inc | POLYTHERAPY FOR THE TREATMENT OF ABNORMAL CELL GROWTH |
| JP2025525935A (ja) * | 2022-08-05 | 2025-08-07 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | 子宮漿液性がんを治療するためのｗｅｅ１化合物 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| WO2025076311A1 (en) * | 2023-10-06 | 2025-04-10 | Zeno Management, Inc. | Solid forms of a wee1 inhibitor |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2338876A1 (en) * | 2009-12-22 | 2011-06-29 | LEK Pharmaceuticals d.d. | Tamsulosin adipate for pharmaceutical use |
| CA3071405A1 (en) | 2017-08-01 | 2019-02-07 | Recurium Ip Holdings, Llc | 1, 2 - dihydro- 3h- pyrazolo [3, 4 - d] pyrimidin -3 - one analogs |
| MX2020009372A (es) | 2018-03-09 | 2020-10-14 | Recurium Ip Holdings Llc | 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas. |
| WO2020210320A1 (en) | 2019-04-11 | 2020-10-15 | Recurium Ip Holdings, Llc | Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
| AU2020384291A1 (en) | 2019-11-15 | 2022-05-26 | Recurium Ip Holdings, Llc | Chiral synthesis of a tertiary alcohol |
| WO2021127039A1 (en) | 2019-12-20 | 2021-06-24 | Recurium Ip Holdings, Llc | Combinations |
| AU2020407070A1 (en) | 2019-12-20 | 2022-07-14 | Recurium Ip Holdings, Llc | Combinations |
| MX2022007623A (es) | 2019-12-20 | 2022-09-23 | Recurium Ip Holdings Llc | Combinaciones. |
| BR112022012280A2 (pt) | 2019-12-20 | 2022-08-30 | Recurium Ip Holdings Llc | Combinações |
| AU2021271844A1 (en) | 2020-05-15 | 2022-12-08 | Recurium Ip Holdings, Llc | Mono- and combination therapies |
| WO2021242667A1 (en) | 2020-05-28 | 2021-12-02 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Optical see-through head-mounted lightfield displays based on substrate-guided combiners |
| EP4153591A4 (en) * | 2020-06-11 | 2024-01-24 | Recurium IP Holdings, LLC | METHOD FOR PRODUCING WEE1 INHIBITOR COMPOUNDS |
| WO2022136916A1 (en) | 2020-12-22 | 2022-06-30 | Recurium Ip Holdings, Llc | Wee1 inhibitors and methods for treating cancer |
| AU2022259496A1 (en) | 2021-04-12 | 2023-10-12 | Recurium Ip Holdings, Llc | Wee1 compound for treating uterine serous carcinoma |
| WO2022251224A1 (en) | 2021-05-28 | 2022-12-01 | Recurium Ip Holdings, Llc | Wee1 inhibitors and methods for treating cancer |
| WO2022271731A1 (en) | 2021-06-23 | 2022-12-29 | Recurium Ip Holdings, Llc | Wee1 inhibitors and methods for treating cancer |
| WO2023064282A1 (en) | 2021-10-13 | 2023-04-20 | Recurium Ip Holdings, Llc | Combinations of wee 1 inhibitors and anti-cd47 antibodies. |
| WO2023076485A1 (en) | 2021-10-28 | 2023-05-04 | Recurium Ip Holdings, Llc | Combination therapies comprising wee1 inhibitors and dna damage response (ddr) inhibitors |
| EP4447965A4 (en) | 2021-12-15 | 2025-12-03 | Recurium Ip Holdings Llc | COMBINATIONS FOR TRIPLE THERAPY OF BCL-2 INHIBITORS, WEE-1 INHIBITORS AND OTHER CHEMOTHERAPEUTIC AGENTS |
| JP2024546569A (ja) | 2021-12-15 | 2024-12-26 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | がんに対するｗｅｅ１阻害剤 |
| KR20240119096A (ko) | 2021-12-15 | 2024-08-06 | 리커리엄 아이피 홀딩스, 엘엘씨 | 암 치료를 위한 병용 요법 사용 |
| JP2025525935A (ja) | 2022-08-05 | 2025-08-07 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | 子宮漿液性がんを治療するためのｗｅｅ１化合物 |
| EP4587026A1 (en) | 2022-09-15 | 2025-07-23 | Recurium IP Holdings, LLC | Combinations |
| TW202421151A (zh) | 2022-09-16 | 2024-06-01 | 美商瑞卡瑞恩Ｉｐ控股有限責任公司 | Ｗｅｅ１抑制劑及用於治療癌症之方法 |
| EP4615459A4 (en) | 2022-11-08 | 2026-04-29 | Zeno Man Inc | Intermittent dosing regimen for azenosertib in treating cancer |
| KR20250094718A (ko) | 2022-11-08 | 2025-06-25 | 제노 매니지먼트, 인크. | Wee1 억제제로 암을 치료하기 위한 예측 바이오마커로서 시클린 e1 상태의 용도 |
| TW202502354A (zh) | 2023-06-02 | 2025-01-16 | 美商薩諾管理公司 | 同源重組修復缺陷（ｈｒｄ）作為預測性生物標記以便使用ｗｅｅ１抑制劑治療癌症 |
| WO2025076311A1 (en) | 2023-10-06 | 2025-04-10 | Zeno Management, Inc. | Solid forms of a wee1 inhibitor |
| WO2025106635A1 (en) | 2023-11-15 | 2025-05-22 | Zeno Management, Inc. | Alteration of f-box and wd repeat domain containing 7 (fbxw7) gene as a predictive biomarker for treating cancer with wee1 inhibitors |
| WO2025179038A1 (en) | 2024-02-21 | 2025-08-28 | Recurium Ip Holdings, Llc | Wee1 inhibitors and methods for treating cancer |
| WO2025184572A1 (en) | 2024-03-01 | 2025-09-04 | Zeno Management, Inc. | Wee1 inhibitor combination therapy |
| WO2025188946A1 (en) | 2024-03-07 | 2025-09-12 | Recurium Ip Holdings, Llc | Wee1 inhibitors and methods for treating cancer |
| WO2025193930A1 (en) | 2024-03-14 | 2025-09-18 | Zeno Management, Inc. | Wee1 inhibitor combination therapy |
-
2021
- 2021-07-08 BR BR112023000350A patent/BR112023000350A2/pt unknown
- 2021-07-08 CN CN202180055999.8A patent/CN116323613A/zh active Pending
- 2021-07-08 CA CA3188737A patent/CA3188737A1/en active Pending
- 2021-07-08 EP EP21838389.1A patent/EP4178960A4/en active Pending
- 2021-07-08 MX MX2023000333A patent/MX2023000333A/es unknown
- 2021-07-08 KR KR1020237004679A patent/KR20230038523A/ko active Pending
- 2021-07-08 AU AU2021305347A patent/AU2021305347A1/en active Pending
- 2021-07-08 US US18/004,628 patent/US12606567B2/en active Active
- 2021-07-08 JP JP2023501229A patent/JP2023533040A/ja active Pending
- 2021-07-08 WO PCT/US2021/070851 patent/WO2022011391A1/en not_active Ceased
- 2021-07-09 TW TW110125370A patent/TWI896701B/zh active
-
2025
- 2025-09-22 JP JP2025156853A patent/JP2025181949A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230265097A1 (en) | 2023-08-24 |
| TWI896701B (zh) | 2025-09-11 |
| NZ796125A (en) | 2025-10-31 |
| MX2023000333A (es) | 2023-03-08 |
| US12606567B2 (en) | 2026-04-21 |
| JP2025181949A (ja) | 2025-12-11 |
| CA3188737A1 (en) | 2022-01-13 |
| BR112023000350A2 (pt) | 2023-03-28 |
| EP4178960A4 (en) | 2024-07-17 |
| WO2022011391A1 (en) | 2022-01-13 |
| JP2023533040A (ja) | 2023-08-01 |
| AU2021305347A1 (en) | 2023-02-16 |
| TW202216716A (zh) | 2022-05-01 |
| EP4178960A1 (en) | 2023-05-17 |
| KR20230038523A (ko) | 2023-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116323613A (zh) | Wee1抑制剂的盐和形式 | |
| CN115335379B (zh) | 含螺环的喹唑啉化合物 | |
| JP7042812B2 (ja) | トリアゾロピリミジン化合物の結晶形態 | |
| WO2023116895A1 (zh) | Kras抑制剂的多晶型物及其制备方法和用途 | |
| EP3502103B1 (en) | Crystal form, salt type of substituted 2-hydro-pyrazole derivative and preparation method therefor | |
| WO2025076311A1 (en) | Solid forms of a wee1 inhibitor | |
| US20240166636A1 (en) | Crystalline compounds and methods of making the same | |
| TW202545956A (zh) | 吡啶並嘧啶類衍生物的晶型、製備方法及其應用 | |
| JP2014533719A (ja) | アプレピタントｌ−プロリン溶媒和化合物−組成物及び共結晶 | |
| CN112239466B (zh) | 选择性cdk4/6抑制剂的琥珀酸盐及其晶型 | |
| EP4056559A1 (en) | Phenyl amino pyrimidine compound or polymorph of salt thereof | |
| RU2858658C2 (ru) | Соли и формы ингибитора wee1 | |
| CN117586282A (zh) | 一种稠合四环类衍生物的可药用盐、晶型及制备方法 | |
| EP4596553A1 (en) | Salt of dioxane quinoline compound, crystal form thereof, preparation methods therefor and uses thereof | |
| AU2015392050B2 (en) | Fumarate of pyridylamine compound and crystals thereof | |
| EP4631937A1 (en) | Crystalline form or amorphous form of oxoisoindole-5-formamide compound or salt and solvate thereof | |
| EP4653445A1 (en) | Cdk inhibitor and crystal form of pharmaceutically acceptable salt thereof, and use thereof | |
| TW202328138A (zh) | 稠合二環類衍生物的可藥用鹽、晶型及其製備方法 | |
| CN117751121A (zh) | 氨基吡唑并嘧啶化合物的晶体 | |
| CN117466898A (zh) | 氨基吡唑并嘧啶化合物的晶体 | |
| CN117794913A (zh) | 嘧啶衍生物及其药学上可接受的盐的多晶型物和应用 | |
| CN115490640A (zh) | 取代的苯并咪唑类化合物及包含该化合物的组合物及其用途 | |
| BR122024009277A2 (pt) | Formas cristalinas de um composto de triazolopirimidina | |
| BR112018076443B1 (pt) | Processo de preparação de formas cristalinas de um composto de triazolopirimidina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |